Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice

Molecular Neurobiology

Volumn 54, Issue 6, 2017, Pages 4160-4171

  Jin, Li ^a   Gao, Li Feng ^b   Sun, Dong Sheng ^a   Wu, Hao ^b   Wang, Qun ^a   Ke, Dan ^a   Lei, Hao ^b   Wang, Jian Zhi ^a,c   Liu, Gong Ping ^a,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan National Laboratory for Optoelectronics   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

Alzheimer s disease; BDNF; Cognitive; Fluoxetine; MRI

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; TAU PROTEIN; ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; DENTATE GYRUS; DRUG EFFECT; HIPPOCAMPAL CA1 REGION; LONG TERM CARE; LONG TERM POTENTIATION; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ALZHEIMER DISEASE; ANIMAL; DRUG EFFECTS; HIPPOCAMPUS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITION DISORDERS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DENDRITIC SPINES; FLUOXETINE; HIPPOCAMPUS; MICE, TRANSGENIC; NEURONAL PLASTICITY; NEURONS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84975318491     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9952-9     Document Type: Article

References (55)

1. Coyle JT, Price DL, DeLong MR (1983) Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190
2. Glenner GG (1988) Alzheimer’s disease: its proteins and genes. Cell 52:307–308
3. Arai H, Lee VM, Otvos L Jr et al (1990) Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. Proc Natl Acad Sci U S A 87:2249–2253
4. Braak H, Braak E (1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1:213–216
5. Thome J, Sakai N, Shin K et al (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 20:4030–4036
6. Tiraboschi E, Tardito D, Kasahara J et al (2004) Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 29:1831–1840
7. Brown AM, Tekkok SB, Ransom BR (2003) Glycogen regulation and functional role in mouse white matter. J Physiol 549:501–512
8. Tekkok SB, Brown AM, Westenbroek R et al (2005) Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity. J Neurosci Res 81:644–652
9. Wang JW, David DJ, Monckton JE et al (2008) Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci 28:1374–1384
10. Begenisic T, Baroncelli L, Sansevero G et al (2014) Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome. Neurobiol Dis 63:12–19
11. Valera E, Ubhi K, Mante M et al (2014) Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia 62:317–337
12. Drzyzga LR, Marcinowska A, Obuchowicz E (2009) Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res Bull 79:248–257
13. Kirkova M, Tzvetanova E, Vircheva S et al (2010) Antioxidant activity of fluoxetine: studies in mice melanoma model. Cell Biochem Funct 28:497–502
14. Mostert JP, Koch MW, Heerings M et al (2008) Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther 14:153–164
15. Mowla A, Mosavinasab M, Pani A (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 27:67–70
16. Taragano FE, Lyketsos CG, Mangone CA et al (1997) A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics 38:246–252
17. Dong H, Goico B, Martin M et al (2004) Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 127:601–609
18. Ivkovic M, Damjanovic A, Jasovic-Gasic M, Paunovic VR (2004) The effects of fluoxetine on cognitive functions in animal model of Alzheimer’s disease. Psychiatr Danub 16:15–20
19. Wang J, Zhang Y, Xu H et al (2014) Fluoxetine improves behavioral performance by suppressing the production of soluble beta-amyloid in APP/PS1 mice. Curr Alzheimer Res 11:672–680
20. Keowkase R, Aboukhatwa M, Luo Y (2010) Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 59:358–365
21. Aboukhatwa M, Luo Y (2011) Antidepressants modulate intracellular amyloid peptide species in N2a neuroblastoma cells. J Alzheimers Dis 24:221–234
22. Yang C, Guo X, Wang GH et al (2014) Changes in tau phosphorylation levels in the hippocampus and frontal cortex following chronic stress. Braz J Med Biol Res 47:237–244
23. Lee HB, Lyketsos CG (2003) Depression in Alzheimer’s disease: heterogeneity and related issues. Biol Psychiatry 54:353–362
24. Migliorelli R, Teson A, Sabe L et al (1995) Prevalence and correlates of dysthymia and major depression among patients with Alzheimer’s disease. Am J Psychiatry 152:37–44
25. Akhisaroglu M, Manev R, Akhisaroglu E et al (2003) Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport 14:1471–1473
26. Ashburner J, Friston KJ (2005) Unified segmentation. Neuroimage 26(3):839–851
27. Ashburner J (2007) A fast diffeomorphic image registration algorithm. Neuroimage 38(1):95–113
28. Jiang X, Chai GS, Wang ZH et al (2015) CaMKII-dependent dendrite ramification and spine generation promote spatial training-induced memory improvement in a rat model of sporadic Alzheimer’s disease. Neurobiol Aging 36:867–876
29. Tollefson GD, Holman SL (1994) How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 9:245–250
30. Thompson C (2002) Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 17(Suppl 1):S27–32
31. Mayberg HS, Brannan SK, Tekell JL et al (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843
32. Martin SJ, Grimwood PD, Morris RG (2000) Synaptic plasticity and memory: an evaluation of the hypothesis. Annu Rev Neurosci 23:649–711
33. Lynch MA (2004) Long-term potentiation and memory. Physiol Rev 84:87–136
34. McAllister AK, Katz LC, Lo DC (1999) Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22:295–318
35. Park H, Poo MM (2013) Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 14:7–23
36. Gomez-Isla T, Price JL, McKeel DW Jr et al (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16:4491–4500
37. Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31–39
38. Santin LJ, Rubio S, Begega A et al (2000) Spatial learning and the hippocampus. Rev Neurol 31:455–462
39. Burgess N, Maguire EA, O’Keefe J (2002) The human hippocampus and spatial and episodic memory. Neuron 35:625–641
40. Shankar GM, Li S, Mehta TH et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842
41. Lee HJ, Kim JW, Yim SV et al (2001) Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry 6(610):725–618
42. Kodama M, Fujioka T, Duman RS (2004) Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56:570–580
43. Czeh B, Muller-Keuker JI, Rygula R et al (2007) Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 32:1490–1503
44. Zusso M, Debetto P, Guidolin D et al (2008) Fluoxetine-induced proliferation and differentiation of neural progenitor cells isolated from rat postnatal cerebellum. Biochem Pharmacol 76:391–403
45. Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365–2372
46. Kovalchuk Y, Hanse E, Kafitz KW, Konnerth A (2002) Postsynaptic induction of BDNF-mediated long-term potentiation. Science 295:1729–1734
47. Bennett MR, Lagopoulos J (2014) Stress and trauma: BDNF control of dendritic-spine formation and regression. Prog Neurobiol 112:80–99
48. Jourdi H, Iwakura Y, Narisawa-Saito M et al (2003) Brain-derived neurotrophic factor signal enhances and maintains the expression of AMPA receptor-associated PDZ proteins in developing cortical neurons. Dev Biol 263:216–230
49. Caldeira MV, Melo CV, Pereira DB et al (2007) BDNF regulates the expression and traffic of NMDA receptors in cultured hippocampal neurons. Mol Cell Neurosci 35:208–219
50. Tartaglia N, Du J, Tyler WJ et al (2001) Protein synthesis-dependent and -independent regulation of hippocampal synapses by brain-derived neurotrophic factor. J Biol Chem 276:37585–37593
51. Kim HJ, Kim W, Kong SY (2013) Antidepressants for neuro-regeneration: from depression to Alzheimer’s disease. Arch Pharm Res 36:1279–1290
52. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
53. Oddo S, Caccamo A, Shepherd JD et al (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421
54. Hunter JM, Bowers WJ, Maarouf CL et al (2011) Biochemical and morphological characterization of the AbetaPP/PS/tau triple transgenic mouse model and its relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 27:361–376
55. Marlatt MW, Potter MC, Bayer TA et al (2013) Prolonged running, not fluoxetine treatment, increases neurogenesis, but does not alter neuropathology, in the 3xTg mouse model of Alzheimer’s disease. Curr Top Behav Neurosci 15:313–340